Understand the source comparison
Do Peptides Help with Psoriasis: Full Comparison
Thymosin alpha-1 Enhances Treg function, reduces IL-17A and TNF-alpha 52.3% mean reduction at 12 weeks (RCT, n=86) 1.6mg subcutaneous twice weekly for 12–16 weeks Subcutaneous injection only Thymalin equivalent formulations KPV (Lys-Pro-Val) Inhibits NF-kB tra
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Thymosin alpha-1
- Enhances Treg function, reduces IL-17A and TNF-alpha
- 52.3% mean reduction at 12 weeks (RCT, n=86)
- 1.6mg subcutaneous twice weekly for 12–16 weeks
- Subcutaneous injection only
- Thymalin equivalent formulations
- KPV (Lys-Pro-Val)
- Inhibits NF-kB translocation, reduces cytokine gene transcription
- 28% mean reduction at 8 weeks (pilot, n=32)
- 500mcg oral daily for 8–12 weeks
- Oral or subcutaneous
- KPV 5MG
- Cartalax (Ala-Glu-Asp)
- Normalises keratinocyte differentiation, reduces epidermal hyperplasia
- 41% PASI-50 at 12 weeks (small trial, n=22)
- 10mg subcutaneous daily for 10 days, cycled
- Cartalax Peptide
- Cathelicidin LL-37 derivatives
- Antimicrobial, potential anti-inflammatory when formulated correctly
- Preclinical only. Elevated endogenous LL-37 correlates with severity
- Not established for therapeutic use
- Topical or subcutaneous (experimental)
- Research-grade synthesis required
- Beta-defensin peptides
- Modulates dendritic cell maturation, reduces Th17 activation
- In vitro evidence only. No human RCTs
- Not established
- Unknown
- Experimental